Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · January 12, 2024

Pharmacokinetics and Pharmacodynamics of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

Diabetes, Obesity & Metabolism

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD
Diabetes Obes Metab 2023 Nov 30;[EPub Ahead of Print], T Eissing, SC Goulooze, P van den Berg, M van Noort, M Ruppert, N Snelder, D Garmann, J Lippert, R Heinig, M Brinker, HJL Heerspink

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading